SynthesisFrontiers in pharmacology2026
Associations of PD-L1 expression status, tumor histology and patient ethnic background with immunotherapy outcomes in patients with advanced esophageal cancer.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Concurrent versus sequential immune checkpoint inhibition in the neoadjuvant treatment of resectable esophageal squamous cell carcinoma: a systematic review and meta-analysis.Clinical and translational radiation oncology · 2027Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Currently, immune checkpoint inhibitors (ICIs) have become a mainstay in treating advanced esophageal cancer (EC), yet the predictive significance of routinely collected clinicopathological characteristics for overall survival (OS) remains uncertain. Methods: We searched EMBASE, MEDLINE, Cochrane Library, Web of Science, and ClinicalTrials.gov for phase III randomized controlled trials (RCTs). Eligible studies reported OS for the overall population and subgroups stratified by various clinicopathological features. Pooled hazard ratios (HRs) and their 95% confidence intervals (CIs) were calculated. Results: A total of 13 phase III RCTs involving 7696 advanced EC patients were included. Pooled analysis showed immunotherapy was associated with favorable outcomes (HR = 0.73; 95% CI, 0.69-0.77; Conclusion: Immunotherapy significantly improves outcomes in advanced esophageal cancer. However, for EAC patients, clinicians must thoughtfully evaluate the treatment effectiveness, safety, and patient preferences to provide personalized management. PD-L1 expression and race tend to be associated with better outcomes rather than acting as a standalone indicator for patient stratification. Other routinely evaluated clinicopathological features showed no significant modulating effect on immunotherapy efficacy. Systematic Review Registration: Identifier CRD420261348582.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.